CoChat
Sign Up
Cited by 38Renal and Vascular PathologiesBlood Pressure and Hypertension StudiesPeripheral Artery Disease Management

Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA‐approved trials

Weinberg, Ido, Keyes, Michelle J., Giri, Jay, Rogers, Kevin R., Olin, Jeffrey W., White, Christopher J., Jaff, Michael R.·2014·Catheterization and Cardiovascular Interventions
DOI 10.1002/ccd.25263
Open this paper in CoChat — free account

Abstract

Background: Renal artery stent revascularization is commonly used for renovascular hypertension. Clinical predictors associated with blood pressure (BP) improvement after renal artery stent revascularization are not well understood. Methods: Patient‐level data from 901 patients in five prospective multicenter Food and Drug Administration‐approved investigational device exemption studies of renal artery stent revascularization was pooled. BP response was defined as reduction of systolic BP (SBP) by >10 mm Hg. Stent patency was defined within each study. Associations of BP reduction were determined by logistic regression. Results: Of 901 patients, complete outcome information was available in 527. Of these, 212/527 (40%) were male, mean age was 63 ± 13 years, 196/544 (36%) were diabetic and 504/527 (96%) had a SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg at baseline. Compared to baseline, 9‐month systolic (164 ± 21 mm Hg vs. 146 ± 22 mm Hg, P < 0.0001) and diastolic (79 ± 13 mm Hg vs. 76 ± 12 mm Hg, P < 0.0001) BP declined significantly. Nine‐month stent patency was 90% (305/339). In a univariate analysis, baseline SBP >150 mm Hg (OR = 4.09, CI = 2.74–6.12, P < 0.0001) was positively associated with BP response following renal artery stent revascularization. In a multivariable analysis, baseline SBP remained associated with a positive BP response (OR = 1.76, CI = 1.53–2.03, P < 0.0001). Conclusions: In the largest pooled dataset of patients treated with renal artery stent revascularization, SBP and DBP were significantly lower at 9‐months. Elevated baseline SBP (>150 mm Hg) was strongly associated with BP reduction after the procedure. © 2013 Wiley Periodicals, Inc.

Integrity signals

Registry

Crossref · 10.1002/ccd.25263

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Restoring main renal artery patency with endovascular stenting is likely to reduce arterial blood pressure, albeit with a residual requirement for antihypertensive drug therapy.

    “Although initial treatment usually includes systematically advancing medical therapy, restoring main renal artery patency with endovascular stenting is also likely to reduce arterial BP, albeit with a residual requirement for antihypertensive drug therapy.316”

    From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [316]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Weinberg, I., Keyes, M. J., Giri, J., Rogers, K. R., Olin, J. W., White, C. J., & Jaff, M. R.
Affiliations
  • Massachusetts General Hospital (US)
  • University of Pennsylvania Health System (US)
  • University of Colorado Denver (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Ochsner Health System (US)
Corresponding author
Jaff, Michael R.
ORCID
Venue
Catheterization and Cardiovascular Interventions
Publisher
Wiley
Published
2013-11-09
Volume
83
Issue
4
Pages
603-609
ISSN
  • 1522-1946 (ISSN-L)
  • 1522-726X
DOI
10.1002/ccd.25263
OpenAlex
W1606804645
Cited by
38
References
32
Citations by year
2022: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 6 · 2014: 7 · 2013: 1
FWCI
0.99
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Catheterization and Cardiovascular Interventions (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
Keywords
renal artery stenting, renovascular hypertension, blood pressure response, systolic blood pressure, baseline blood pressure, stent patency
MeSH terms
Aged, Blood Pressure, Female, Humans, Hypertension, Renovascular, Male, Middle Aged, Prospective Studies, Renal Artery Obstruction, Risk Factors, Time Factors, United States, United States Food and Drug Administration, Multicenter Studies as Topic, Stents, Multivariate Analysis, Chi-Square Distribution, Logistic Models, Odds Ratio, Treatment Outcome, Endovascular Procedures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review